Investing

Abivax : ABVX

ABVX

Stock Data

$101.65

$2.50 (2.52%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Abivax is a Paris-based biotech firm founded in 2013, dedicated to creating treatments that leverage the body's immune system to fight chronic inflammatory diseases. Its flagship product, obefazimod, is currently in Phase 3 trials, targeting the treatment of ulcerative colitis. By focusing on the body's natural regulatory mechanisms, Abivax aims to offer innovative solutions for patients with severe health conditions.

All Abivax Articles

1 Article

Lee Jackson | Jun 2, 2026 at 8:11 AM EDT

Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More

Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices…